$72.2 M

KMPH Mkt cap, 21-Sep-2018
KemPharm Net income (Q2, 2018)-36.2 M
KemPharm EBIT (Q2, 2018)-28.7 M
KemPharm Cash, 30-Jun-201816.5 M

KemPharm Income Statement

Annual

USDFY, 2015FY, 2016

R&D expense

4.7 m20.5 m

General and administrative expense

2.6 m14 m

Operating expense total

7.3 m34.5 m

EBIT

(7.3 m)(37.5 m)

Pre tax profit

(9.2 m)(16.5 m)

Income tax expense

1 k15 k

Net Income

(54.7 m)(16.5 m)

Quarterly

USDQ1, 2018Q2, 2018

R&D expense

11.6 m22.1 m

General and administrative expense

3.1 m6.6 m

Operating expense total

14.8 m28.7 m

EBIT

(14.8 m)(28.7 m)

Interest income

115 k238 k

Pre tax profit

(26.2 m)(36.3 m)

Income tax expense

8 k47 k

Net Income

(26.2 m)(36.2 m)

KemPharm Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

32.3 m16.8 m

Inventories

2.8 m489 k

Current Assets

54.1 m74.4 m

PP&E

403 k2 m

Total Assets

55.7 m84.9 m

Accounts Payable

4.9 m6.4 m

Current Liabilities

8.3 m6.6 m

Total Liabilities

103.6 m

Additional Paid-in Capital

94.7 m102.6 m

Retained Earnings

(104.8 m)(121.3 m)

Total Equity

(10.1 m)(18.7 m)

Financial Leverage

-5.5 x-4.5 x

Quarterly

USDQ3, 2017Q1, 2018Q2, 2018

Cash

8.8 m16.5 m

Inventories

1.4 m

Current Assets

39.1 m30.9 m

PP&E

1.9 m1.8 m

Total Assets

42.6 m34 m

Accounts Payable

6.4 m10.2 m14 m

Current Liabilities

13.8 m17.6 m

Total Liabilities

122.3 m117.5 m

Additional Paid-in Capital

111.3 m117.4 m

Retained Earnings

(190.9 m)(200.9 m)

Total Equity

(79.7 m)(83.5 m)

Financial Leverage

-0.5 x-0.4 x

KemPharm Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(54.7 m)(16.5 m)

Depreciation and Amortization

84 k175 k

Accounts Receivable

(4.5 m)

Inventories

(1.2 m)(15.9 m)

Accounts Payable

1.3 m1.1 m

Cash From Operating Activities

(20.3 m)(29.8 m)

Purchases of PP&E

(135 k)(643 k)

Cash From Investing Activities

(19.1 m)(46.9 m)

Cash From Financing Activities

61.5 m61.2 m

Interest Paid

3 k3.3 m

Quarterly

USDQ1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

1.4 m

Accounts Payable

4 m4.9 m4.2 m5.4 m5.6 m4.6 m6.3 m6.4 m

KemPharm Ratios

USDY, 2018

Financial Leverage

-0.4 x
Report incorrect company information